High purity steviol glycosides
The biocatalytic method uses UDP-glucosyltransferase to convert steviol glycoside substrate into high-purity target steviol glycoside, which solves the problem that the existing methods are not suitable for commercialization, and achieves the efficient and economical preparation of steviol glycoside and Highly purified.
Patent Information
- Application Number
- CN201910173608.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2012-05-22
- Filing Date
- 2013-03-12
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2033-03-12
AI Technical Summary
The existing preparation methods for steviol glycosides are not suitable for commercial use and lack simple, efficient and economical preparation methods.
Using biocatalytic method, the starting composition containing the steviol glycoside substrate is contacted with UDP-glucosyltransferase to produce a target steviol glycoside containing additional glucose units. The catalysis of UDP-glucosyltransferase is achieved. High-efficiency biotransformation of glycosides.
High purification and efficient preparation of steviol glycosides are achieved, and high-purity steviol glycoside compositions are provided, suitable for consumable products such as food and beverages.
Smart Images

Figure CN110358795B_ABST
Abstract
Description
[0001] This application is a divisional application of Chinese invention patent application No. 201380002119.6. Technical Field
[0002] The present invention relates to a biocatalytic method for preparing compositions comprising steviol glycosides, including highly purified steviol glycoside compositions.
[0003] Incorporation by Reference into the Sequence Listing
[0004] The text file entitled "PureCircle_22PCT_ST25.txt," created on March 12, 2013, having 5 KB (kilobytes) of data and filed concurrently herewith, is incorporated by reference in its entirety into this application. Background of the Invention
[0005] High-intensity sweeteners have a sweetness level many times higher than that of sucrose. They are essentially caloric-free and are commonly used in diet and low-calorie products, including food and beverages. High-intensity sweeteners do not trigger a glycemic response, making them suitable for use in products for diabetics and other products aimed at controlling carbohydrate intake.
[0006] Steviol glycosides are a class of compounds found in the leaves of stevia rebaudiana Bertoni, a perennial shrub in the Asteraceae (Compositae) family native to certain areas of South America. Their structure is characterized by a single base, steviol, and differs by the presence of carbohydrate residues at positions C13 and C19. They accumulate in Stevia leaves, constituting approximately 10%-20% of the total dry weight. The four major glycosides generally found in Stevia leaves, based on dry weight, include stevioside (9.1%), rebaudioside A (3.8%), rebaudioside C (0.6-1.0%), and dulcoside A (0.3%). Other known steviol glycosides include rebaudioside B, C, D, E, F, and X, steviolbioside, and rubusoside.
[0007] Although methods for preparing steviol glycosides from Stevia are known, most of these methods are not suitable for commercial use.
[0008] Therefore, there remains a need for simple, efficient, and economical methods for preparing compositions comprising steviol glycosides, including highly purified steviol glycoside compositions. SUMMARY OF THE INVENTION
[0009] The present invention provides a biocatalytic method for preparing a composition comprising a target steviol glycoside by contacting a starting composition comprising a steviol glycoside substrate with a UDP-glucosyltransferase, thereby producing a composition comprising a target steviol glycoside, wherein the target steviol glycoside comprises one or more additional glucose units compared to the steviol glycoside substrate.
[0010] The starting composition can be any composition comprising at least one steviol glycoside substrate. In one embodiment, the steviol glycoside substrate is selected from steviol monoside, steviol diglycoside, rubusoside, dulcoside B, dulcoside A, rebaudioside B, rebaudioside G, stevioside, rebaudioside C, rebaudioside F, rebaudioside A, rebaudioside I, rebaudioside E, rebaudioside H, rebaudioside L, rebaudioside K, rebaudioside J, rebaudioside X, rebaudioside D, rebaudioside N, rebaudioside O, a synthetic steviol glycoside, or a combination thereof. The starting composition can be commercially available or prepared. The starting composition can comprise a purified steviol glycoside substrate or a partially purified steviol glycoside substrate.
[0011] In one embodiment, the steviol glycoside substrate is rubusoside.
[0012] In another embodiment, the steviol glycoside substrate is stevioside.
[0013] In another embodiment, the steviol glycoside substrate is rebaudioside A.
[0014] In another embodiment, the steviol glycoside substrate is rebaudioside D.
[0015] The target steviol glycoside can be any known steviol glycoside. In one embodiment, the target steviol glycoside is steviol monoside, steviol diside, rubusoside, dulcoside B, dulcoside A, rebaudioside B, rebaudioside G, stevioside, rebaudioside C, rebaudioside F, rebaudioside A, rebaudioside I, rebaudioside E, rebaudioside H, rebaudioside L, rebaudioside K, rebaudioside J, rebaudioside X, rebaudioside D, rebaudioside N, rebaudioside O, or a synthetic steviol glycoside.
[0016] In one embodiment, the target steviol glycoside is stevioside.
[0017] In another embodiment, the target steviol glycoside is rebaudioside A.
[0018] In another embodiment, the target steviol glycoside is rebaudioside D.
[0019] In another embodiment, the target steviol glycoside is Rebaudioside X.
[0020] The UDP-glucosyltransferase can be any UDP-glucosyltransferase that can add at least one glucose unit to a steviol glycoside substrate to provide a target steviol glycoside. In one embodiment, the UDP-glucosyltransferase is produced in a host. The host can be, for example, a species of Escherichia coli (E. coli), a species of Saccharomyces spp., a species of Aspergillus sp., or a species of Pichia sp. In another embodiment, the UDP-glucosyltransferase is synthesized.
[0021] The UDP-glucosyltransferase can be provided in any suitable form, including free, immobilized form or as a complete cell system. The purity of the UDP-glucosyltransferase can vary, for example, it can be provided as a crude, semi-purified or purified enzyme preparation.
[0022] In one embodiment, the UDP-glucosyltransferase is free. In another embodiment, the UDP-glucosyltransferase is fixed, for example, fixed on an inorganic or organic support. In another embodiment, the UDP-glucosyltransferase is provided in the form of a complete cell system (for example, as a living microbial cell) or in the form of a cell lysate.
[0023] In one embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rubusoside to form stevioside. In a specific embodiment, the UDP-glucosyltransferase is UGT91D2.
[0024] In one embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to stevioside to form rebaudioside A. In a specific embodiment, the UDP-glucosyltransferase is UGT76G1.
[0025] In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside A to form rebaudioside D. In a specific embodiment, the UDP-glucosyltransferase is UGT91D2.
[0026] In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside D to form rebaudioside X. In a specific embodiment, the UDP-glucosyltransferase is UGT76G1.
[0027] Optionally, the method of the present invention also includes recycling UDP to produce UDP-glucose. In one embodiment, the method includes recycling UDP by providing a recycling catalyst and a recycling substrate, thereby using a catalytic amount of UDP-glucosyltransferase and UDP-glucose to carry out the bioconversion of steviol glycoside substrate to target steviol glycoside ( Figure 3 ).
[0028] In one embodiment, the recycling catalyst is sucrose synthase.
[0029] In one embodiment, the recycled substrate is sucrose.
[0030] Optionally, the method of the present invention further comprises separating the target steviol glycoside from the starting composition. The target steviol glycoside can be separated by any appropriate method such as crystallization, separation by membrane, centrifugation, extraction, chromatography or a combination of such methods.
[0031] In one embodiment, the separation produces a composition comprising greater than about 80% of the target steviol glycoside by dry weight, i.e., a highly purified steviol glycoside composition. In another embodiment, the separation produces a composition comprising greater than 90% of the target steviol glycoside by weight. In a specific embodiment, the composition comprises greater than about 95% of the target steviol glycoside by weight.
[0032] The target steviol glycoside may exist in any polymorphic or amorphous form, including hydrates, solvates, anhydrous forms, or combinations thereof.
[0033] The purified target steviol glycosides can be used as sweeteners in consumable products. Suitable consumable products include, but are not limited to, foods, beverages, pharmaceutical compositions, smoking products, nutritional product compositions, oral hygiene compositions, and cosmetic compositions. Summary of the Figures
[0034] The accompanying drawings are included to provide a further understanding of the present invention. The accompanying drawings illustrate embodiments of the present invention and together with the description serve to explain the principle of the embodiments of the present invention.
[0035] Figure 1 The structure of reb X is shown.
[0036] Figure 2 The biocatalytic production of reb X from stevioside is shown.
[0037] Figure 3 Biocatalytic production of reb A from stevioside using the enzyme UGT76G1 is shown, along with concomitant recycling of UDP to UDP-glucose by sucrose synthase.
[0038] Figure 4The IR spectrum of reb X is shown.
[0039] Figure 5 HPLC chromatogram showing the products of the biocatalytic production of reb X from reb D, as described in Example 14. The peak with a retention time of 24.165 minutes corresponds to unreacted reb D. The peak with a retention time of 31.325 minutes corresponds to reb X.
[0040] Figure 6 Shown is the HPLC chromatogram of purified reb X produced from reb D by biocatalysis.
[0041] Figure 7 HPLC chromatogram of reb X standard is shown.
[0042] Figure 8 HPLC chromatogram showing co-injection of reb X standard and reb X purified from biotransformation of reb D.
[0043] Figure 9 Shown are reb X standards and purified reb X after biotransformation with reb D. 1 Superposition of H NMR spectra.
[0044] Figure 10 Shown is the HRMS spectrum of reb X purified after biocatalytic production from reb D.
[0045] Figure 11 Shown is the conversion of stevioside to Reb A catalyzed by UGT76G1 as measured by CAD.
[0046] Figure 12 Shown is the synthesis of rebaudioside X from rebaudioside D catalyzed by in vitro produced UGT76G1 / CAD detection. Detailed description
[0047] The present invention provides a biocatalytic method for preparing a composition comprising a target steviol glycoside from a starting composition comprising a steviol glycoside substrate, wherein the target steviol glycoside comprises one or more additional glucose units compared to the steviol glycoside substrate.
[0048] An object of the present invention is to provide an efficient biocatalytic process for preparing steviol glycosides, particularly stevioside, reb A, reb D and reb X, from other steviol glycosides and / or mixtures thereof.
[0049] As used herein, "biocatalysis" or "biocatalytic" refers to the chemical transformation of organic compounds using natural catalysts, such as enzyme proteins. Biocatalysis may also be referred to as biotransformation or biosynthesis. Both isolated and whole-cell biocatalysis methods are known in the art. The biocatalyst enzyme protein can be a naturally occurring or recombinantly produced protein.
[0050] As used herein, the term "steviol glycoside" refers to glycosides of steviol, including but not limited to naturally occurring steviol glycosides, such as steviol monoside, steviol diside, rubusoside, dulcoside B, dulcoside A, rebaudioside B, rebaudioside G, stevioside, rebaudioside C, rebaudioside F, rebaudioside A, rebaudioside I, rebaudioside E, rebaudioside H, rebaudioside L, rebaudioside K, rebaudioside J, rebaudioside X, rebaudioside D, rebaudioside N, rebaudioside O, synthetic steviol glycosides, such as enzymatically glucosylated steviol glycosides, and combinations thereof.
[0051] Chemical structures of steviol and its glycosides
[0052]
[0053]
[0054] (Glc = glucose)
[0055] Starting composition
[0056] As used herein, "starting composition" refers to any composition (typically an aqueous solution) comprising one or more steviol glycosides, wherein the one or more steviol glycosides are used as substrates for bioconversion.
[0057] In one embodiment, the starting composition comprises one or more steviol glycosides selected from steviol monoside, steviol diside, rubusoside, dulcoside B, dulcoside A, rebaudioside B, rebaudioside G, stevioside, rebaudioside C, rebaudioside F, rebaudioside A, rebaudioside I, rebaudioside E, rebaudioside H, rebaudioside L, rebaudioside K, rebaudioside J, rebaudioside X, rebaudioside D, rebaudioside N, rebaudioside O, or a synthetic steviol glycoside. In a specific embodiment, the starting composition comprises two or more steviol glycosides.
[0058] In one embodiment, the starting composition comprises the steviol glycoside substrate rubusoside.
[0059] In one embodiment, the starting composition comprises the steviol glycoside substrate stevioside.
[0060] In another embodiment, the starting composition comprises the steviol glycoside substrate rebaudioside A.
[0061] In another embodiment, the starting composition comprises the steviol glycoside substrate rebaudioside D.
[0062] The starting composition can be synthesized or purified (partially or completely), commercially available or prepared. An example of a starting composition for the method of the present invention is an extract obtained from the purification of stevia plant material (e.g., leaves). Another example of a starting composition is a commercially available stevia extract that forms a solution with a solvent. Another example of a starting composition is a mixture of commercially available steviol glycosides that forms a solution with a solvent. Other suitable starting compositions include by-products of methods for separating and purifying steviol glycosides.
[0063] In one embodiment, the starting composition comprises a purified steviol glycoside substrate. For example, the starting composition may comprise greater than about 99% of a specific substrate steviol glycoside by dry weight.
[0064] In another embodiment, the starting composition comprises a partially purified substrate steviol glycoside composition. For example, the starting composition comprises more than about 50%, about 60%, about 70%, about 80% or about 90% of the specific substrate steviol glycoside by dry weight.
[0065] In one embodiment, the starting composition comprises purified rubusoside. In a specific embodiment, the starting composition comprises greater than 99% rubusoside by dry weight. In another embodiment, the starting composition comprises partially purified rubusoside. In a specific embodiment, the starting composition comprises greater than about 50%, about 60%, about 70%, about 80%, or about 90% rubusoside by dry weight.
[0066] In one embodiment, the starting composition comprises purified stevioside. In a specific embodiment, the starting composition comprises greater than 99% stevioside by dry weight. In another embodiment, the starting composition comprises partially purified stevioside. In a specific embodiment, the starting composition comprises greater than about 50%, about 60%, about 70%, about 80%, or about 90% stevioside by dry weight.
[0067] In another embodiment, the starting composition comprises purified rebaudioside A. In a specific embodiment, the starting composition comprises greater than about 99% rebaudioside A by dry weight. In another embodiment, the starting composition comprises partially purified rebaudioside A. In a specific embodiment, the starting composition comprises greater than about 50%, about 60%, about 70%, about 80%, or about 90% rebaudioside A by dry weight.
[0068] In another embodiment, the starting composition comprises purified rebaudioside D. In a specific embodiment, the starting composition comprises greater than about 99% rebaudioside D by dry weight. In another embodiment, the starting composition comprises partially purified rebaudioside D. In a specific embodiment, the starting composition comprises greater than about 50%, about 60%, about 70%, about 80%, or about 90% rebaudioside D by dry weight.
[0069] The steviol glycoside component of the starting composition is used as a substrate for producing a target steviol glycoside, as described herein. The target steviol glycoside is chemically different from its corresponding steviol glycoside substrate by the addition of one or more glucose units.
[0070] Target steviol glycosides
[0071] The target steviol glycoside of the present invention can be any steviol glycoside that can be prepared by the method disclosed herein. In one embodiment, the target steviol glycoside is selected from steviol monoside, steviol diside, rubusoside, dulcoside B, dulcoside A, rebaudioside B, rebaudioside G, stevioside, rebaudioside C, rebaudioside F, rebaudioside A, rebaudioside I, rebaudioside E, rebaudioside H, rebaudioside L, rebaudioside K, rebaudioside J, rebaudioside X, rebaudioside D, rebaudioside N or rebaudioside O.
[0072] In one embodiment, the target steviol glycoside is stevioside. In another embodiment, the target steviol glycoside is reb A. In another embodiment, the target steviol glycoside is reb D. In another embodiment, the target steviol glycoside is reb X.
[0073] The target steviol glycoside may be in any polymorphic or amorphous form, including hydrates, solvates, anhydrous forms, or combinations thereof.
[0074] In one embodiment, the present invention is a biocatalytic method for producing stevioside from rubusoside, wherein the starting composition comprises the steviol glycoside substrate rubusoside. In a specific embodiment, the present invention is a biocatalytic method for producing stevioside from rubusoside, wherein the starting composition comprises partially purified rubusoside. In another specific embodiment, the present invention is a biocatalytic method for producing stevioside from rubusoside, wherein the starting composition comprises purified rubusoside.
[0075] In one embodiment, the present invention is a biocatalytic method for producing reb A from stevioside, wherein the starting composition comprises the steviol glycoside substrate stevioside. In a specific embodiment, the present invention is a biocatalytic method for producing reb A from stevioside, wherein the starting composition comprises partially purified stevioside. In another specific embodiment, the present invention is a biocatalytic method for producing reb A from stevioside, wherein the starting composition comprises purified stevioside.
[0076] In another embodiment, the present invention is a biocatalytic method for producing reb D from reb A, wherein the starting composition comprises the steviol glycoside substrate reb A. In a specific embodiment, the present invention is a biocatalytic method for producing reb D from reb A, wherein the starting composition comprises partially purified reb A. In another specific embodiment, the present invention is a biocatalytic method for producing reb D from reb A, wherein the starting composition comprises purified reb A.
[0077] In another embodiment, the present invention is a biocatalytic method for producing reb X from reb D, wherein the starting composition comprises the steviol glycoside substrate reb D. In a specific embodiment, the present invention is a biocatalytic method for producing reb X from reb D, wherein the starting composition comprises partially purified reb D. In another specific embodiment, the present invention is a biocatalytic method for producing reb X from reb D, wherein the starting composition comprises purified reb D.
[0078] In a specific embodiment, the target steviol glycoside is present in a mixture. For example, in one embodiment, the target steviol glycoside is Reb X present in the mixture. In one embodiment, the purity of the target steviol glycoside is increased relative to the purity of the target steviol glycoside present in the starting composition. For example, the method of the present invention results in an increase in the purity of Reb X present in the starting composition.
[0079] Optionally, the method of the present invention further comprises isolating the target steviol glycoside from the starting composition. The target steviol glycoside can be isolated by any appropriate method such as crystallization, separation by membrane, centrifugation, extraction, chromatography or a combination of such methods.
[0080] In certain embodiments, the methods disclosed herein produce highly purified target steviol glycoside compositions. As used herein, the term "highly purified" refers to compositions having greater than about 80% target steviol glycosides by dry weight. In one embodiment, the highly purified target steviol glycoside composition comprises greater than about 90% target steviol glycosides by dry weight, for example, 91%, greater than about 92%, greater than about 93%, greater than about 94%, greater than about 95%, greater than about 95%, greater than about 97%, greater than about 98%, or greater than about 99% target steviol glycoside content by dry weight.
[0081] In a more specific embodiment, when the target steviol glycoside is reb X, the methods described herein provide a composition having a reb X content of greater than about 90% by dry weight. In another specific embodiment, when the target steviol glycoside is reb X, the methods described herein provide a composition comprising a reb X content of greater than about 95% by dry weight.
[0082] In another specific embodiment, when the target steviol glycoside is reb D, the methods described herein provide a composition having a reb D content of more than about 90% by dry weight. In another specific embodiment, when the target steviol glycoside is reb D, the methods described herein provide a composition comprising a reb D content of more than about 95% by dry weight.
[0083] In another specific embodiment, when the target steviol glycoside is reb A, the methods described herein provide a composition comprising greater than about 90% reb A content by dry weight. In another specific embodiment, when the target steviol glycoside is reb A, the methods described herein provide a composition comprising greater than about 95% reb A content by dry weight.
[0084] In another specific embodiment, when the target steviol glycoside is stevioside, the methods described herein provide a composition comprising a stevioside content of greater than about 90% by dry weight. In another specific embodiment, when the target steviol glycoside is stevioside, the methods described herein provide a composition comprising a stevioside content of greater than about 95% by dry weight.
[0085] In one embodiment, the biocatalytic process of the invention is performed more than once, whereby the target steviol glycoside produced by a first biocatalytic process is used as a steviol glycoside substrate for a second biocatalytic process in which the target steviol glycoside is produced (which can also be considered an intermediate target steviol glycoside).
[0086] In certain embodiments, the present invention provides a biocatalytic method for preparing a composition comprising a target steviol glycoside by: contacting a starting composition comprising a steviol glycoside substrate with a UDP-glucosyltransferase, thereby producing a composition comprising an intermediate target steviol glycoside (which comprises one or more additional glucose units compared to the steviol glycoside substrate); contacting the composition comprising the intermediate target steviol glycoside with a UDP-glucosyltransferase, thereby producing a target steviol glycoside comprising one or more additional glucose units compared to the intermediate target steviol glycoside. Depending on the number of times the method is performed, there may be one or more intermediate target steviol glycosides (e.g., a first intermediate target steviol glycoside, a second intermediate target steviol glycoside, a third intermediate target steviol glycoside) that participate in the production of the target steviol glycoside.
[0087] UDP-glucosyltransferase
[0088] The method of the present invention is biocatalytic, i.e., utilizes a biocatalyst. In one embodiment, the biocatalyst is an enzyme protein. In a specific embodiment, the biocatalyst is a UDP-glucosyltransferase. The UDP-glucosyltransferase can be any UDP-glucosyltransferase that is capable of adding at least one glucose unit to a steviol glycoside substrate to provide a target steviol glycoside.
[0089] In one embodiment, the UDP-glucosyltransferase is produced in a host, for example, a microorganism. For example, the DNA sequence encoding the UDP-glucosyltransferase is cloned into an expression vector and subsequently transferred into a production host, for example, a microorganism, for example, a bacterium. The non-limiting examples of suitable hosts include species of Escherichia coli, Saccharomyces, species of Aspergillus, and species of Pichia. Based on its physical and chemical properties, techniques known in the art can be used to separate the expressed protein from cell extracts. Representative non-limiting techniques for separating the UDP-glucosyltransferase from the host include centrifugation, electrophoresis, liquid chromatography, ion exchange chromatography, gel filtration chromatography, or affinity chromatography.
[0090] UDP-glucosyltransferase can be provided as crude, semi-purified and purified enzyme preparations.
[0091] In one embodiment, the UDP-glucosyltransferase is free. In another embodiment, the UDP-glucosyltransferase is fixed. For example, the UDP-glucosyltransferase can be fixed to a solid support made from an inorganic or organic material. The non-limiting examples of the solid support that is suitable for fixing the UDP-glucosyltransferase include deutero-cellulose or glass, ceramics, metal oxide or film. The UDP-glucosyltransferase can be fixed to a solid support, for example, by covalent attachment, adsorption, crosslinking, capture or encapsulation.
[0092] The reaction medium used for conversion is typically aqueous, such as purified water, a buffer, or a combination thereof. In a specific embodiment, the reaction medium is a buffer. Suitable buffers include, but are not limited to, PIPES buffer, acetate buffer, and phosphate buffer. In a specific embodiment, the reaction medium is a phosphate buffer. Alternatively, the reaction medium can also be an organic solvent.
[0093] In one embodiment, the UDP-glucosyltransferase is provided in the form of a whole cell system, such as a living microbial cell. Likewise, the whole cell system may optionally be immobilized using the techniques described above for the immobilization of the enzyme.
[0094] In one embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rubusoside, thereby producing stevioside. The UDP-glucosyltransferase can be, for example, UGT91D2.
[0095] In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to stevioside, thereby producing rebaudioside A. The UDP-glucosyltransferase can be, for example, UGT76G1.
[0096] In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside A, thereby producing rebaudioside D. The UDP-glucosyltransferase can be, for example, UGT91D2.
[0097] In another embodiment, the UDP-glucosyltransferase is any UDP-glucosyltransferase capable of adding at least one glucose unit to rebaudioside D, thereby producing rebaudioside X. The UDP-glucosyltransferase can be, for example, UGT76G1.
[0098] Optionally, the method of the present invention further comprises recycling UDP to provide UDP-glucose. In one embodiment, the method comprises recycling UDP by providing a recycling catalyst (i.e., a biocatalyst capable of overproducing UDP-glucose) and a recycling substrate, thereby enabling conversion of a substrate steviol glycoside to a target steviol glycoside using a catalytic amount of UDP-glucosyltransferase and UDP-glucose ( Figure 3 ).
[0099] In one embodiment, the UDP-glucose recycling catalyst is sucrose synthase.
[0100] In one embodiment, the recycled substrate is sucrose.
[0101] Conversion of rubusoside to stevioside
[0102] In one embodiment, a starting composition comprising rubusoside is contacted with a UDP-glucosyltransferase capable of catalyzing the reaction of UDP-glucose and rubusoside to produce stevioside. In one embodiment, the starting composition comprises partially purified rubusoside. In another embodiment, the starting composition comprises purified rubusoside. In a specific embodiment, the starting composition comprises more than 99% rubusoside. In a specific embodiment, the starting composition comprises more than about 50%, about 60%, about 70%, about 80% or about 90% rubusoside.
[0103] In a specific embodiment, the UDP-glucosyltransferase is UGT91D2, which has been described by Joseph et al. (Genbank Accession No. ACE87855). It should be noted that a similar sequence was later described in patent application PCT / US2011 / 038967 and designated UGT91D2e. UGT91D2e shares greater than 95% identity with UGT91D11 (Genbank Accession No. AAR06918) and greater than 99% identity with the UGT of Joseph et al. (Genbank Accession No. ACE87855).
[0104] In some embodiments, UDP-glucosyltransferases such as UGT91D2 are produced by expression in a host microorganism. Suitable host microorganisms include, but are not limited to, Escherichia coli, Saccharomyces species, Aspergillus species, and Pichia species. In a specific embodiment, UGT91D2 is expressed in E. coli.
[0105] UDP-glucosyltransferases such as UGT91D2 can be provided in free or immobilized form. The enzyme preparation can be crude, semi-purified, or purified. In one embodiment, the UDP-glucosyltransferase is provided as a complete cell system (e.g., living microbial cells or complete microbial cells), a cell lysate, and / or in any other form known in the art.
[0106] The reaction medium used for conversion is typically aqueous and can be purified water, buffer or a combination thereof. In a specific embodiment, the reaction medium is a buffer. Suitable buffers include but are not limited to PIPES buffer, acetate buffer and phosphate buffer. In one embodiment, the reaction medium is a phosphate buffer.
[0107] In one embodiment, the conversion of rubusoside to stevioside further comprises adding compounds other than UDP-glucose, rubusoside, and UDP-glucosyltransferase. For example, in some embodiments, the reaction medium comprises MgCl2 and / or MnCl2.
[0108] The reaction can be carried out at a temperature of about 0° C. to about 60° C., for example, about 10° C., about 20° C., about 30° C., about 40° C., about 50° C., or about 60° C. In a particular embodiment, the reaction is carried out at about 30° C.
[0109] The reaction can be carried out for 1 hour to 1 week, for example, about 6 hours, about 12 hours, about 24 hours, about 48 hours, about 72 hours, about 120 hours, about 3 days, about 4 days, about 5 days, about 6 days or about 7 days. In certain embodiments, the reaction is carried out for about 120 hours.
[0110] Optionally, UDP-glucose used as glucose donor can be recycled by using sucrose synthase ( Figure 3 ). Rubusoside is converted to stevioside using UDP-glucose recycled by the reaction between sucrose and UDP. Therefore, rubusoside and sucrose are used in stoichiometric amounts, while UDP is present in a catalytic amount.
[0111] The reaction can be monitored by appropriate methods including, but not limited to, HPLC, LCMS, TLC, IR, or NMR.
[0112] In one embodiment, the conversion of rubusoside to stevioside is at least about 2% complete, as determined by any of the above methods. In a specific embodiment, the conversion of rubusoside to stevioside is at least about 10% complete, at least about 20% complete, at least about 30% complete, at least about 40% complete, at least about 50% complete, at least about 60% complete, at least about 70% complete, at least about 80% complete, at least about 90% complete. In a specific embodiment, the conversion of rubusoside to stevioside is at least about 95% complete.
[0113] Conversion of stevioside to reb A
[0114] In one embodiment, a starting composition comprising stevioside is contacted with a UDP-glucosyltransferase capable of catalyzing the reaction of UDP-glucose with stevioside to produce reb A. Chemically, a glucose unit is added to the disaccharide at the C13 position of stevioside to provide reb A. In one embodiment, the starting composition comprises partially purified stevioside. In another embodiment, the starting composition comprises purified stevioside. In a specific embodiment, the starting composition comprises greater than 99% stevioside. In a specific embodiment, the starting composition comprises greater than about 50%, about 60%, about 70%, about 80%, or about 90% stevioside.
[0115] In certain embodiments, the UDP-glucosyltransferase is UGT76G1. UGT76G1 has been described by Richman et al. (Richman, A., Swanson, A., Humphrey, T., Chapman, R., McGarvey, B., Pocs, R., Brandle, J. Functional genomics uncovers three glucosyltransferases involved in the synthesis of the major sweet glucosides of stevia rebaudiana. The Plant Journal, 2005, 41, 56-67) and is available in Genbank (ACT33422.1) and Uniprot (C7EA09). This enzyme was overexpressed in E. coli and shown to convert stevioside to reb A.
[0116] In some embodiments, a UDP-glucosyltransferase, such as UGT76G1, can be prepared by expressing it in a host microorganism. Suitable host microorganisms include, but are not limited to, Escherichia coli, Saccharomyces species, Aspergillus species, and Pichia species. In a specific embodiment, UGT76G1 is expressed in E. coli.
[0117] UDP-glucosyltransferases such as UGT76G1 can be free or immobilized. They can exist in the form of crude, semi-purified and purified enzyme preparations. UDP-glucosyltransferases can also be provided in the form of intact cell systems (e.g., living microbial cells, intact microbial cells) or cell lysates and / or any other form known in the art.
[0118] The reaction medium used for conversion is typically aqueous and can be purified water, buffer or a combination thereof. In a specific embodiment, the reaction medium is a buffer. Suitable buffers include but are not limited to PIPES buffer, acetate buffer and phosphate buffer. In one embodiment, the reaction medium is a phosphate buffer.
[0119] In one embodiment, the conversion of stevioside to reb A further comprises adding a compound other than UDP-glucose, stevioside, and UDP-glucosyltransferase. For example, in some embodiments, the reaction medium comprises MgCl2 and / or MnCl2.
[0120] The reaction can be carried out at a temperature of about 0° C. to about 60° C., for example, about 10° C., about 20° C., about 30° C., about 40° C., about 50° C., or about 60° C. In a particular embodiment, the reaction is carried out at about 30° C.
[0121] The reaction can be carried out continuously for 1 hour to 1 week, for example, about 6 hours, about 12 hours, about 24 hours, about 48 hours, about 72 hours, about 120 hours, about 3 days, about 4 days, about 5 days, about 6 days or about 7 days. In certain embodiments, the reaction is carried out for about 120 hours.
[0122] Optionally, UDP-glucose used as glucose donor can be recycled by using sucrose synthase ( Figure 3 ). Stevioside is converted to reb A using UDP-glucose recycled through the reaction between sucrose and UDP. Thus, stevioside and sucrose are used in stoichiometric amounts, while UDP is present in catalytic amounts.
[0123] The reaction can be monitored by appropriate methods including, but not limited to, HPLC, LCMS, TLC, IR, or NMR.
[0124] In one embodiment, the biocatalytic conversion or bioconversion of stevioside to reb A is at least about 50% complete, as measured by any of the methods mentioned above. In a specific embodiment, the conversion of stevioside to reb A is at least about 60% complete, at least about 70% complete, at least about 80% complete, or at least about 90% complete. In a specific embodiment, the conversion of stevioside to reb A is at least about 95% complete.
[0125] Conversion of reb A to reb D
[0126] In one embodiment, a starting composition comprising reb A is contacted with a UDP-glucosyltransferase capable of catalyzing the reaction of UDP-glucose with reb A to produce reb D. Chemically, a glucose unit is added to the monosaccharide at the C19 position of reb A to provide reb D. In one embodiment, the starting composition comprises partially purified reb A. In another embodiment, the starting composition comprises purified reb A. In a specific embodiment, the starting composition comprises more than 99% reb A. In a specific embodiment, the starting composition comprises more than about 50%, about 60%, about 70%, about 80%, or about 90% reb A.
[0127] In a specific embodiment, the UDP-glucosyltransferase is UGT91D2, which has been described by Joseph et al. (Genbank Accession No. ACE87855). It should be noted that a similar sequence was later described in patent application PCT / US2011 / 038967 and designated UGT91D2e. UGT91D2e shares greater than 95% identity with UGT91D11 (Genbank Accession No. AAR06918) and greater than 99% identity with the UGT of Joseph et al. (Genbank Accession No. ACE87855).
[0128] In some embodiments, a UDP-glucosyltransferase, such as UGT91D2, is produced by expression in a host microorganism. Suitable host microorganisms include, but are not limited to, Escherichia coli, Saccharomyces species, Aspergillus species, and Pichia species. In a specific embodiment, UGT91D2 is expressed in E. coli.
[0129] UDP-glucosyltransferases such as UGT91D2 can be provided in free or immobilized form. The enzyme preparation can be crude, semi-purified, or purified. In one embodiment, the UDP-glucosyltransferase is provided as a complete cell system (e.g., living microbial cells or complete microbial cells), a cell lysate, and / or in any other form known in the art.
[0130] The reaction medium used for conversion is typically aqueous and can be purified water, buffer or a combination thereof. In a specific embodiment, the reaction medium is a buffer. Suitable buffers include but are not limited to PIPES buffer, acetate buffer and phosphate buffer. In one embodiment, the reaction medium is a phosphate buffer.
[0131] In one embodiment, the conversion of reb A to reb D further comprises adding a compound other than UDP-glucose, reb A, and UDP-glucosyltransferase. For example, in some embodiments, the reaction medium comprises MgCl2 and / or MnCl2.
[0132] The reaction can be carried out at a temperature of about 0° C. to about 60° C., for example, about 10° C., about 20° C., about 30° C., about 40° C., about 50° C., or about 60° C. In a particular embodiment, the reaction is carried out at about 30° C.
[0133] The reaction can be carried out for 1 hour to 1 week, such as about 6 hours, about 12 hours, about 24 hours, about 48 hours, about 72 hours, about 120 hours, about 3 days, about 4 days, about 5 days, about 6 days or about 7 days. In certain embodiments, the reaction is carried out for about 120 hours.
[0134] Optionally, UDP-glucose used as glucose donor can be recycled by using sucrose synthase ( Figure 3 ). Reb A is converted to reb D using UDP-glucose recycled through the reaction between sucrose and UDP. Thus, reb A and sucrose are used in stoichiometric amounts, while UDP is present in catalytic amounts.
[0135] The reaction can be monitored by appropriate methods including, but not limited to, HPLC, LCMS, TLC, IR, or NMR.
[0136] In one embodiment, the conversion of reb A to reb D is at least about 2% complete, as determined by any of the above methods. In a specific embodiment, the conversion of reb A to reb D is at least about 10% complete, at least about 20% complete, at least about 30% complete, at least about 40% complete, at least about 50% complete, at least about 60% complete, at least about 70% complete, at least about 80% complete, at least about 90% complete. In a specific embodiment, the conversion of reb A to reb D is at least about 95% complete.
[0137] Transformation of reb D to reb X
[0138] In one embodiment, the starting composition comprises reb D, which is contacted with a UDP-glucosyltransferase capable of catalyzing the reaction of UDP-glucose with reb D to produce reb X. Chemically, a glucose unit is added to the disaccharide at the C19 position of reb D to provide reb X. In one embodiment, the starting composition comprises partially purified reb D. In another embodiment, the starting composition comprises purified reb D. In a specific embodiment, the starting composition comprises more than 99% reb D. In a specific embodiment, the starting composition comprises more than about 50%, about 60%, about 70%, about 80% or about 90% reb D. In a specific embodiment, the UDP-glucosyltransferase is UGT76G1.
[0139] In some embodiments, a UDP-glucosyltransferase, such as UGT91D2, can be prepared by expressing it in a host microorganism. Suitable host microorganisms include, but are not limited to, Escherichia coli, Saccharomyces species, Aspergillus species, and Pichia species. In specific embodiments, UGT91D2 is expressed in Escherichia coli.
[0140] UDP-glucosyltransferases such as UGT91D2 can be provided in free or immobilized form. The enzyme preparation can be crude, semi-purified, or purified. In one embodiment, the UDP-glucosyltransferase is provided as a whole cell preparation, such as living microbial cells, or in the form of whole microbial cells, as a cell lysate, and / or in any other form known in the art.
[0141] The reaction medium used for conversion is typically aqueous and can be purified water, buffer or a combination thereof. In a specific embodiment, the reaction medium is a buffer. Suitable buffers include but are not limited to PIPES buffer, acetate buffer and phosphate buffer. In one embodiment, the reaction medium is a phosphate buffer.
[0142] In one embodiment, the conversion of reb D to reb X also uses compounds other than UDP-glucose, reb D, and UDP-glucosyltransferase. For example, in some embodiments, the reaction medium comprises MgCl2 and / or MnCl2.
[0143] The reaction can be carried out at a temperature of about 0° C. to about 60° C., for example, about 10° C., about 20° C., about 30° C., about 40° C., about 50° C., or about 60° C. In a particular embodiment, the reaction is carried out at about 30° C.
[0144] The reaction can be carried out for 1 hour to 1 week, such as about 6 hours, about 12 hours, about 24 hours, about 48 hours, about 72 hours, about 120 hours, about 3 days, about 4 days, about 5 days, about 6 days or about 7 days. In certain embodiments, the reaction is carried out for about 120 hours.
[0145] Optionally, UDP-glucose used as glucose donor can be recycled by using sucrose synthase ( Figure 3 ). Reb D is converted to reb X using UDP-glucose recycled through the reaction between sucrose and UDP. Therefore, reb D and sucrose are used in stoichiometric amounts, while UDP is present in catalytic amounts.
[0146] The reaction can be monitored by appropriate methods including, but not limited to, HPLC, LCMS, TLC, IR, or NMR.
[0147] In one embodiment, the conversion of reb D to reb X is at least about 50% complete, as determined by any of the above methods. In a specific embodiment, the conversion of reb D to reb X is at least about 60% complete, at least about 70% complete, at least about 80% complete, or at least about 90% complete. In a specific embodiment, the conversion of reb D to reb X is at least about 95% complete.
[0148] Optionally, the target steviol glycoside is purified from the composition of the obtained. From the reaction medium, the target steviol glycoside can be purified by any appropriate method to provide a highly purified target steviol glycoside composition. Suitable methods include crystallization, separation by membrane, centrifugation, extraction (liquid phase or solid phase), chromatographic separation, HPLC (preparative or analytical) or a combination of these methods.
[0149] In one embodiment, specific biocatalytic conversion can be quenched to terminate the reaction. The resulting mixture is then centrifuged. The supernatant typically contains the target steviol glycoside and, if necessary, can be further purified. For example, analytical or preparative HPLC can be used to separate the remaining target or starting steviol glycoside or reaction byproducts from the target steviol glycoside. In one embodiment, separation is achieved by analytical HPLC. In another embodiment, separation is achieved by preparative HPLC. Those skilled in the art will appreciate that the specific HPLC method used can vary based on specific systems, solvents, and columns. A suitable system for separating reb X from reb D is provided in Example 20.
[0150] The method provided herein can also be repeated, wherein when the method is performed for the second time, the composition produced by the initial treatment (i.e., a composition comprising the target steviol glycoside) can be used as a starting composition, or optionally, the target steviol glycoside can be purified from a composition comprising the target steviol glycoside to provide a highly purified target steviol glycoside or steviol glycoside composition. According to this embodiment, the target steviol glycoside produced when the method is performed for the first time can be used as the first target steviol glycoside or an intermediate target steviol glycoside and used as a substrate for producing a second target steviol glycoside, a second intermediate target steviol glycoside, or a final target steviol glycoside. The method can be repeated multiple times as needed to obtain the final target steviol glycoside. In one embodiment, the method is repeated once. In another embodiment, the method is repeated 2 times. In another embodiment, the method is repeated 3 times. In other embodiments, the method is repeated 4, 5, 6, 7, 8, or 9 times. Those skilled in the art understand that the specific UDP-glucosyltransferase used in each reaction can be the same or different, depending on the specific site on the steviol glycoside substrate to which glucose is to be added.
[0151] Thus, in one embodiment, the method is repeated once, wherein the starting composition of the first method comprises reb A and the target steviol glycoside is reb D, and, wherein the starting composition of the second method comprises reb D and the target steviol glycoside is reb X.
[0152] In another embodiment, the method is repeated 2 times, wherein the starting composition of the first method comprises stevioside and the target steviol glycoside is reb A; the starting composition of the second method comprises reb A and the target steviol glycoside is reb D; and the starting composition of the third method comprises reb D and the target steviol glycoside is reb X.
[0153] In another embodiment, the method is repeated three times, wherein the starting composition of the first method comprises rubusoside and the target steviol glycoside is stevioside; the starting composition of the second method comprises stevioside and the target steviol glycoside is reb A; the starting composition of the third method comprises reb A and the target steviol glycoside is reb D; and the starting composition of the fourth method comprises reb D and the target steviol glycoside is reb X.
[0154] In one embodiment, a method for producing a highly purified target steviol glycoside composition comprises:
[0155] a. contacting a first starting composition comprising a steviol glycoside substrate with a first UDP-glucosyltransferase to produce a composition comprising a first target steviol glycoside;
[0156] b. optionally separating the first target steviol glycoside from the medium to provide a highly purified first target steviol glycoside composition;
[0157] c. contacting a composition comprising a first target steviol glycoside or a highly purified first target steviol glycoside composition with a second UDP-glucosyltransferase to produce a composition comprising a second target steviol glycoside;
[0158] d. optionally separating the second target steviol glycoside from the medium to provide a highly purified second target steviol glycoside composition;
[0159] e. contacting the composition comprising a second target steviol glycoside or a highly purified second target steviol glycoside composition with a third UDP-glucosyltransferase to produce a composition comprising a third target steviol glycoside; and
[0160] f. Optionally separating the third target steviol glycoside from the medium to provide a highly purified third target steviol glycoside composition.
[0161] In one embodiment, the first starting composition comprises stevioside, the first target steviol glycoside is reb A, and the first UDP-glucosyltransferase is UGT76G1.
[0162] In other embodiments, the second UDP-glucosyltransferase is UGT91D2 and the second target steviol glycoside is reb D.
[0163] In other embodiments, the third UDP-glucosyltransferase is UGT91D2 and the third target steviol glycoside is reb X.
[0164] In one embodiment, one or more steps of contacting a composition comprising a steviol glycoside substrate with a UDP-glucosyltransferase further comprises providing a biocatalyst capable of UDP-overproduction and recycling and a substrate for said recycling.
[0165] In a more specific embodiment, a method for producing a highly purified target steviol glycoside composition comprises:
[0166] a. contacting a first starting composition comprising a steviol glycoside substrate with a first UDP-glucosyltransferase to produce a composition comprising a first target steviol glycoside;
[0167] b. optionally providing a biocatalyst capable of overproduction and recycling of UDP and a substrate for recycling;
[0168] c. optionally separating the first target steviol glycoside from the medium to provide a highly purified first target steviol glycoside composition;
[0169] d. contacting a composition comprising a first target steviol glycoside or a highly purified first target steviol glycoside composition with a second UDP-glucosyltransferase to produce a composition comprising a second target steviol glycoside;
[0170] e. optionally providing a biocatalyst capable of overproduction and recycling of UDP and a substrate for said recycling;
[0171] f. optionally separating the second target steviol glycoside from the medium to provide a highly purified second target steviol glycoside composition;
[0172] g. contacting a composition comprising a second target steviol glycoside or a highly purified second target steviol glycoside composition with a third UDP-glucosyltransferase to produce a composition comprising a third target steviol glycoside; and
[0173] h. optionally separating the third target steviol glycoside from the medium to provide a highly purified third target steviol glycoside composition.
[0174] In one embodiment, the first starting composition comprises stevioside, the first target steviol glycoside is reb A, and the first UDP-glucosyltransferase is UGT76G1.
[0175] In other embodiments, the second UDP-glucosyltransferase is UGT91D2 and the second target steviol glycoside is reb D.
[0176] In other embodiments, the third UDP-glucosyltransferase is UGT91D2 and the third target steviol glycoside is reb X.
[0177] In another specific embodiment, a method for producing a highly purified target steviol glycoside composition comprises:
[0178] a. contacting a first starting composition comprising a steviol glycoside substrate with a first UDP-glucosyltransferase to produce a composition comprising a first target steviol glycoside;
[0179] b. optionally providing a biocatalyst capable of overproduction and recycling of UDP and a substrate for said recycling;
[0180] c. optionally separating the first target steviol glycoside from the medium to provide a highly purified first target steviol glycoside composition;
[0181] d. contacting a composition comprising a first target steviol glycoside or a highly purified first target steviol glycoside composition with a second UDP-glucosyltransferase to produce a composition comprising a second target steviol glycoside;
[0182] e. optionally providing a biocatalyst capable of overproduction and recycling of UDP and a substrate for said recycling;
[0183] f. optionally separating the second target steviol glycoside from the medium to provide a highly purified second target steviol glycoside composition;
[0184] g. contacting a composition comprising a second target steviol glycoside or a highly purified second target steviol glycoside composition with a third UDP-glucosyltransferase to produce a composition comprising a third target steviol glycoside; and
[0185] h. optionally providing a biocatalyst capable of overproduction and recycling of UDP and a substrate for said recycling;
[0186] i. optionally separating the third target steviol glycoside from the medium to provide a highly purified third target steviol glycoside composition;
[0187] j. contacting a composition comprising a third target steviol glycoside or a highly purified third target steviol glycoside composition with a fourth UDP-glucosyltransferase to produce a composition comprising a fourth target steviol glycoside; and
[0188] k. optionally providing a biocatalyst capable of overproduction and recycling of UDP and a substrate for said recycling;
[0189] 1. Optionally separating the fourth target steviol glycoside from the medium to provide a highly purified fourth steviol glycoside composition.
[0190] In one embodiment, the first starting composition comprises rubusoside, the first target steviol glycoside is stevioside, and the first UDP-glucosyltransferase is UGT91D2.
[0191] In other embodiments, the second UDP-glucosyltransferase is UGT76G1 and the second target steviol glycoside is reb A.
[0192] In other embodiments, the third UDP-glucosyltransferase is UGT91D2 and the third target steviol glycoside is reb D.
[0193] In other embodiments, the fourth UDP-glucosyltransferase is UGT91D2 and the fourth target steviol glycoside is reb X.
[0194] Purified steviol glycosides prepared according to the present invention can be used in a variety of products, including but not limited to foods, beverages, pharmaceutical compositions, smoking products, nutraceutical compositions, oral hygiene compositions, and cosmetic compositions.
[0195] The high-purity reb X obtained in the present invention (having a molecular weight of 1291.29, C 56 H 90 O 33 The molecular formula and Figure 1 The structure shown in Figure 2 is present as a white, odorless powder. When compared with a 10% sucrose solution, the compound is about 200 times sweeter than sugar. The infrared absorption spectrum is shown in Figure 2. Figure 4 middle.
[0196] Other properties of pure reb X compounds include a melting point of 249-250°C and [α] D 25 The specific optical rotation (C=1.0) is -19.0° (in 50% ethanol). The solubility of reb X in water is about 0.3%, and increases with increasing temperature.
[0197] Reb X is soluble in dilute solutions of methanol, ethanol, n-propanol, and isopropanol. However, it is insoluble in acetone, benzene, chloroform, and diethyl ether.
[0198] Reb X obtained according to the present invention is heat and pH stable.
[0199] The highly purified target glycosides obtained according to the present invention, particularly reb D and / or reb X, can be used "as is" or in combination with other sweeteners, flavors, and food ingredients.
[0200] Non-limiting examples of flavors include lime, lemon, orange, fruit, banana, grape, pear, pineapple, mango, almond, cola, cinnamon, sugar, cotton candy, and vanilla flavors.
[0201] Non-limiting examples of other food ingredients include flavors, acidulants, organic and amino acids, colorants, fillers, modified starches, gums, texturizers, preservatives, antioxidants, emulsifiers, stabilizers, thickeners, and gelling agents.
[0202] The highly purified target glycosides obtained according to the present invention, particularly reb D and / or reb X, can be prepared in various polymorphic forms, including but not limited to hydrates, solvates, anhydrous forms, amorphous forms and / or mixtures thereof.
[0203] The highly purified target steviol glycosides obtained according to the present invention, particularly reb D and / or reb X, can be incorporated into food, beverages, pharmaceutical compositions, cosmetics, chewing gum, table top products, cereals, dairy products, toothpaste and other oral compositions as high-intensity natural sweeteners.
[0204] The highly purified target steviol glycosides, particularly reb D and / or reb X, as sweetening compounds can be used as the sole sweetener, or they can be used in combination with other naturally occurring high intensity sweeteners, such as stevioside, reb A, reb B, reb C, reb D, reb E, reb F, stevioside, dulcoside A, rubusoside, mogroside, sweet protein, neohesperidin dihydrochalcone, glycyrrhizic acid and its salts, thaumatin, perilla sugar, pernandulcin, mukuroziosides, baiyuanshen glycoside, styracoside-I, dimethyl-hexahydrofluorene-dicarboxylic acid, abrusosides, brazilicyrrhizin, carnosiflosides, smilaxoside, pterocaryoside, polypodioside A, brazilin, hernandulcin, phillodulcin, smilaxoside, phloridzin, trilobatin, dihydroflavonol, dihydroquercetin-3-acetate, neoastilibin, trans-cinnamaldehyde, monatin and its salts, selligueain A, hematoxylin, moniglycoprotein, polypodium sweetener, pterocaryoside A, pterocaryoside B. Mabinin, pentadin, flavor-modifying glycoprotein, curculin, neoculin, chlorogenic acid, cynarin, monk fruit sweetener, mogroside V, simonoside, etc.
[0205] Highly purified target steviol glycosides, particularly reb D and / or reb X, can also be used in combination with synthetic high-intensity sweeteners, for example, sucralose, acesulfame potassium, aspartame, alitame, saccharin, neohesperidin dihydrochalcone, cyclamate, neotame, glycine, suosan, N-[N-[3-(3-hydroxy-4-methoxyphenyl)propyl]-L-α-aspartyl]-L-phenylalanine 1-methyl ester, N-[N-[3-(3-hydroxy-4-methoxyphenyl)-3-methylbutyl]-L-α-aspartyl]-L-phenylalanine 1-methyl ester, N-[N-[3-(3-methoxy-4-hydroxyphenyl)propyl]-L-α-aspartyl]-L-phenylalanine 1-methyl ester, salts thereof, and the like.
[0206] In addition, highly purified target steviol glycosides, particularly reb D and / or reb X, can be used in combination with natural sweetener inhibitors, such as gymnemic acid, dextrin, ziziphin, lactisole, etc. Reb D and / or reb X can also be combined with various umami enhancers. Reb D and / or reb X can be mixed with umami and sweet amino acids such as glutamic acid, aspartic acid, glycine, alanine, threonine, proline, serine, glutamate, and tryptophan.
[0207] Highly purified target steviol glycosides, particularly reb D and / or reb X, can also be combined with polyols or sugar alcohols. The term "polyol" refers to a molecule containing more than one hydroxyl group. A polyol can be a diol, triol, or tetraol containing 2, 3, and 4 hydroxyl groups, respectively. A polyol can also contain more than four hydroxyl groups, such as pentaols, hexaols, heptaols, etc., containing 5, 6, or 7 hydroxyl groups, respectively. In addition, a polyol can also be a sugar alcohol, a polyhydric alcohol, or a polyalcohol, which is a reduced form of a carbohydrate in which a carbonyl group (aldehyde or ketone, reducing sugar) is reduced to a primary or secondary alcohol hydroxyl group. Examples of polyols include, but are not limited to, erythritol, maltitol, mannitol, sorbitol, lactitol, xylitol, inositol, isomalt, propylene glycol, glycerol, threitol, galactitol, hydrogenated isomaltulose, reduced isomalt-oligosaccharides, reduced xylo-oligosaccharides, reduced gentio-oligosaccharides, reduced maltose syrup, reduced glucose syrup, hydrogenated starch hydrolysate, hydrogenated glucose and sugar alcohols or any other carbohydrate that can be reduced without adversely affecting the taste of the sweetener composition.
[0208] Highly purified target steviol glycosides, particularly reb D and / or reb X, can be combined with reduced-calorie sweeteners such as D-tagatose, L-glucose, L-sorbose, L-arabinose, and the like.
[0209] Highly purified target steviol glycosides, particularly reb D and / or reb X, can also be combined with various carbohydrates. The term "carbohydrate" generally refers to an aldehyde or ketone compound substituted with multiple hydroxy groups, having the general formula (CH2O) n, wherein n is 3-30, and oligomers and polymers thereof. In addition, the carbohydrates of the present invention may be substituted or deoxygenated at one or more positions. As used herein, carbohydrates include unmodified carbohydrates, carbohydrate derivatives, substituted carbohydrates, and modified carbohydrates. As used herein, the phrases "carbohydrate derivatives," "substituted carbohydrates," and "modified carbohydrates" are synonymous. Modified carbohydrates refer to any carbohydrate in which at least one atom is added, removed, or substituted, or a combination thereof. Thus, carbohydrate derivatives or substituted carbohydrates include substituted and unsubstituted monosaccharides, disaccharides, oligosaccharides, and polysaccharides. The carbohydrate derivative or substituted carbohydrate can optionally be deoxygenated at any corresponding C-position and / or can be substituted with one or more moieties, such as hydrogen, halogen, haloalkyl, carboxyl, acyl, acyloxy, amino, amide, carboxyl derivative, alkylamino, dialkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfhydryl, sulfhydryl, imino, sulfonyl, sulfenyl, sulfenyl, sulfamoyl, alkoxycarbonyl, carboxamido, phosphonyl, phosphinyl, phosphoryl, phosphino, thioester, thioether, oxime, hydrazine, carbamoyl, phosphate, phosphonato, or any other reactive functional group, so long as the carbohydrate derivative or substituted carbohydrate is capable of improving the sweet taste of the sweetener composition.
[0210] Examples of carbohydrates that can be used according to the present invention include, but are not limited to, tagatose, trehalose, galactose, rhamnose, various cyclodextrins, cyclic oligosaccharides, various types of maltodextrins, dextran, sucrose, glucose, ribulose, fructose, threose, arabinose, xylose, lyxose, allose, altrose, mannose, idose, lactose, maltose, invert sugar, isotrehalose, neotrehalose, isomaltulose, erythrose, deoxyribose, threonose, maltodextrin ... Sugar, gulose, idose, talose, erythrulose, xylulose, psicose, turanose, cellobiose, amylopectin, glucosamine, mannosamine, fucose, glucuronic acid, gluconic acid, gluconolactone, abequose, galactosamine, beet oligosaccharides, isomaltose oligosaccharides (isomaltose, isomaltotriose, panose, etc.), xylooligosaccharides (xylotriose, xylobiose, etc.), xylose-terminated oligosaccharides (xylo-terminated oligosaccharides, x ...
[0014] The present invention also includes oligosaccharides, gentiooligosaccharides (gentiobiose, gentiotriose, gentiotetraose, etc.), sorbose, niger oligosaccharides, palatinose oligosaccharides, fructo-oligomers (kestose, mold erythrothrose, etc.), maltotetraol, maltotriol, malto-oligosaccharides (maltotriose, maltotetraose, maltopentaose, maltohexaose, maltoheptaose, etc.), starch, inulin, inulin oligosaccharides, lactulose, melibiose, raffinose, ribose, isomerized liquid sugars such as high fructose corn syrup, coupling sugars and soy oligosaccharides. In addition, the carbohydrates used herein can be D or L configuration.
[0211] The highly purified target steviol glycosides obtained according to the invention, particularly reb D and / or reb X, can be used in combination with various physiologically active substances or functional ingredients. Functional ingredients are generally divided into categories such as carotenoids, dietary fiber, fatty acids, saponins, antioxidants, nutraceuticals, flavonoids, isothiocyanates, phenols, phytosterols and stanols (plant sterols and phytostanols); polyols; prebiotics, probiotics; phytoestrogens; soy protein; sulfides / thiols; amino acids; proteins; vitamins; and minerals. Functional ingredients can also be classified based on their health benefits (e.g., cardiovascular, cholesterol-lowering, and anti-inflammatory).
[0212] The highly purified target steviol glycosides obtained according to the present invention, particularly reb D and / or reb X, can be used as high-intensity sweeteners for producing zero-calorie, reduced-calorie or diabetic beverages and foods (with improved taste characteristics). They can also be used in beverages, foods, medicines, and other products in which sugar cannot be used. In addition, the highly purified target steviol glycosides, particularly reb D and / or reb X, can also be used as sweeteners, not only for beverages, foods, and other products specifically for human consumption, but also for animal feed and fodder with improved characteristics.
[0213] Examples of products in which the highly purified target steviol glycosides, particularly reb D and / or reb X, can be used as sweetening compounds include, but are not limited to, alcoholic beverages such as vodka, wine, beer, liquor, and sake; natural juices; energy drinks; carbonated soft drinks; diet drinks; zero-calorie drinks; reduced-calorie drinks and foods; yogurt drinks; instant juices; instant coffee; powdered instant drinks; canned products; syrups; fermented bean paste; soybean sauce; vinegar; dressings; mayonnaise; ketchup; curry products; soups; instant bouillon; powdered soybean sauce; powdered vinegar; various types of biscuits; rice crackers; crackers; bread; chocolate; caramel; candy; chewing gum; jelly; pudding; pickled fruits and vegetables; fresh cream; jam; marmalade; flower flower ingredients paste); milk powder; ice cream; sorbet; vegetables and fruits packaged in bottles; canned and boiled beans; meat and food cooked in sweet sauces; agricultural vegetable food; seafood; ham; sausage; fish ham; fish sausage; fish paste; fried fish products; dried seafood products; frozen food; preserved seaweed; cured meat; tobacco; medicine; etc. In principle, it has unlimited applications.
[0214] In the manufacture of products such as food, beverages, medicines, cosmetics, table top products and chewing gum, conventional methods such as mixing, kneading, dissolving, pickling, infiltration, percolation, spraying, atomizing, pouring and the like can be used.
[0215] In addition, the highly purified target steviol glycosides obtained according to the present invention, particularly reb D and / or reb X, can be used in dry or liquid form. They can be added before or after heat treatment of food. The amount of the highly purified target steviol glycosides, particularly reb D and / or reb X, depends on the purpose of use. As described above, they can be added alone or in combination with other compounds.
[0216] The following examples illustrate preferred embodiments of the present invention for preparing highly purified target steviol glycosides, particularly reb D and / or reb X. It should be understood that the present invention is not limited to the materials, proportions, conditions, and methods shown in the examples, which are merely exemplary.
[0217] Example 1
[0218] In vivo production of UGT76G1
[0219] NcoI and NdeI restriction sites were added to the original nucleic acid sequence described in Genbank accession number AAR06912.1. After codon optimization, the following nucleic acid sequence (SEQ ID NO.1) was obtained:
[0220] Sequence Listing
[0221]
[0222]
[0223] After synthesizing the gene and subcloning it into the pET30A+ vector using the NdeI and XhoI cloning sites, the UGT76Gl_pET30a+ plasmid was introduced into E. coli B121 (DE3) and E. coli EC 100 by electroporation. The obtained cells were cultured in a culture dish in the presence of kanamycin, and appropriate colonies were selected and grown in liquid LB medium (Erlenmeyer flasks). Glycerol was added to the suspension as an antifreeze, and 400 μL aliquots were stored at -20°C and -80°C.
[0224] A stock aliquot of E. coli BL21 (DE3) containing the pET30A+_UGT76G1 plasmid was thawed and added to 30 mL of LBGKP medium (20 g / L Luria Broth Lennox; 50 mM PIPES buffer pH 7.00; 50 mM phosphate buffer pH 7.00; 2.5 g / L glucose and 50 mg / L kanamycin). The culture was shaken at 30° C. and 135 rpm for 8 h.
[0225] The production medium contained 60 g / L of overnight express instant TB medium (Novagen), 10 g / L glycerol, and 50 mg / L kanamycin. The medium was stirred at 20°C while samples were collected to measure OD and pH. The culture grew significantly and achieved a good OD. After 40 hours, the cells were harvested by centrifugation and frozen to a wet cell weight of 12.7 g.
[0226] Lysis was performed by adding Bugbuster Master mix (Novagen), and the lysate was recovered by centrifugation and kept frozen. Activity assays were performed using thawed lysate.
[0227] Example 2
[0228] In vitro production of UGT76G1
[0229] The S30 T7 High Yield Protein Expression System kit from Promega was used. 4 μg of UGT76G1_pET30a+ plasmid from E. coli EC100 was mixed with 80 μL of S30 premix plus and 72 μL of S30 T7 extract was added. Nuclease-free water was added to a total volume of 200 μL, and the resulting solution was incubated at 30°C for 2 hours. 180 μL was used for the catalytic test reaction.
[0230] Example 3
[0231] In vitro production of UGT91D2
[0232] NcoI and NdeI restriction sites were added to the original nucleic acid sequence described in Genbank accession number ACE87855.1. After codon optimization, the following nucleic acid sequence (SEQ ID NO.2) was obtained:
[0233] Sequence Listing
[0234]
[0235]
[0236] After synthesizing the gene and subcloning it into the pET30A+ vector using the NcoI and Xho1 cloning sites, the UGT91D2_pET30a+ plasmid was introduced into E. coli EC100 by electroporation. The obtained cells were cultured in the presence of kanamycin, and appropriate colonies were selected and grown in liquid LB medium (Erlenmeyer flasks). Glycerol was added to the suspension as an antifreeze, and 400 μL aliquots were stored at -20°C and -80°C.
[0237] The S30 T7 High Yield Protein Expression System kit from Promega was used for in vitro protein synthesis.
[0238] 4 μg of UGT91D2_pET30a+ plasmid was mixed with 80 μL of S30 premix plus and 72 μL of S30T7 extract was added. Nuclease-free water was added to a total volume of 200 μL, and the resulting solution was incubated at 30°C for 2 hours. 5 μL was used for SDS-PAGE analysis, and the remaining 45 μL was used for the catalytic test reaction.
[0239] Example 4
[0240] Utilizes the catalytic reaction of UGT76G1 produced in vivo
[0241] The total volume of the reaction was 5.0 mL and had the following composition: 50 mM sodium phosphate buffer pH 7.2, 3 mM MgCl , 2.5 mM UDP-glucose, 0.5 mM stevioside, and 500 μL of thawed UGT76G1 lysate. The reaction was run on an orbital shaker at 135 rpm at 30° C. For each sample, 460 μL of the reaction mixture was quenched with 40 μL of 2N H 2 SO 4 and 420 μL of methanol / water (6 / 4). The sample was immediately centrifuged, maintained at 10° C., and subsequently analyzed by HPLC (CAD). HPLC showed almost complete conversion of stevioside to rebaudioside A.
[0242] Example 5
[0243] Catalytic reactions using in vitro generated UGT91D2
[0244] The total reaction volume was 0.5 mL and had the following composition: 50 mM sodium phosphate buffer, pH 7.2, 3 mM MgCl2, 3.8 mM UDP-glucose, 0.1 mM rebaudioside A, and 180 μL of in vitro-produced UGT91D2. The reaction was run at 30°C on an orbital shaker at 135 rpm. For each sample, 450 μL of the reaction mixture was quenched with 45 μL of 2N H2SO4 and 405 μL of 60% MeOH. After centrifugation, the supernatant was analyzed by HPLC (CAD). HPLC showed that after 120 hours, 4.7% of rebaudioside A was converted to rebaudioside D.
[0245] Example 6
[0246] Catalytic reactions using in vitro generated UGT76G1
[0247] The total reaction volume was 2 mL and had the following composition: 50 mM sodium phosphate buffer, pH 7.2, 3 mM MgCl2, 3.8 mM UDP-glucose, 0.5 mM rebaudioside D, and 180 μL of in vitro-produced UGT76G1. The reaction was run at 30°C on an orbital shaker at 135 rpm. For each sample, 400 μL of the reaction mixture was quenched with 40 μL of 2N H2SO4 and 360 μL of 60% MeOH. After centrifugation, the supernatant was analyzed by HPLC (CAD). HPLC showed that after 120 hours, 80% of the rebaudioside D was converted to rebaudioside X.
[0248] For Examples 7 to 12, the following abbreviations are used:
[0249] LBGKP medium: 20 g / L Luria Broth Lennox; 50 mM PIPES buffer pH 7.00; 50 mM phosphate buffer pH 7.00; 2.5 g / L glucose and 50 mg / L kanamycin or ampicillin
[0250] LB medium: (20g / L Luria Broth Lennox)
[0251] Example 7
[0252] Preparation and activity of UGT76G1 produced using the pET30a+ plasmid and BL21(DE3) expression strain
[0253] The pET30a+_UGT76G1 plasmid was transformed into the BL21 (DE3) expression strain (Lucigen E. EXPRESS Electrocompetent Cells. The obtained cells were cultured in a Petri dish on LB agar in the presence of kanamycin. Appropriate colonies were selected and grown in liquid LBGKP medium containing kanamycin. Glycerol was added and 400 μL aliquots were stored at -20°C and -80°C.
[0254] The stored aliquot was thawed and added to 30 mL of LBGKP medium. The culture was shaken at 30°C for 8 hours and then used to inoculate 400 mL of production medium containing 60 g / L "Overnight Expression Instant TB Medium" (Novagen, catalog number 71491-5), 10 g / L glycerol, and 50 mg / L kanamycin. The medium was stirred at 20°C, and samples were collected to measure OD (600 nm) and pH. After 40 hours, the cells were harvested by centrifugation and frozen. The resulting wet cell weight was 10.58 g.
[0255] 3.24 g of the obtained pellet were lysed by adding 8.1 mL of Bugbuster Master mix (Novagen, catalog number 71456) and 3.5 mL of water. The lysate was recovered by centrifugation and kept frozen.
[0256] Example 8
[0257] Preparation and activity of UGT76G1 prepared using pET30a+ plasmid and Tuner (DE3) expression strain
[0258] The pET30a+_UGT76G1 plasmid was transformed into the Tuner (DE3) expression strain (Novagen Tuner tm(DE3 competent cells). The obtained cells were cultured on LB agar in a Petri dish in the presence of kanamycin. Appropriate colonies were selected and grown in liquid LBGKP medium containing kanamycin. Glycerol was added and 400 μL aliquots were stored at -20°C and -80°C.
[0259] The stored aliquot was thawed and added to 100 mL of LB medium containing 50 mg / L kanamycin. The culture was shaken at 30°C for 15 h. 4.4 mL of the culture was used to inoculate 200 mL of production medium containing LB. The medium was stirred at 37°C until an OD (600 nm) of 0.9 was obtained, after which 400 μL of 100 mM IPTG solution was added and the medium was stirred at 30°C for 4 hours. The cells were harvested by centrifugation and frozen. The resulting cell wet weight was 1.38 g.
[0260] The obtained pellet was lysed by adding 4.9 mL of "Bugbuster Master mix (Novagen, catalog number 71456) and 2.1 mL of water. The lysate was recovered by centrifugation and kept frozen.
[0261] Example 9
[0262] Preparation and activity of UGT76G1 produced using the pMAL plasmid and BL21 expression strain
[0263] After subcloning the synthesized UGT76G1 gene into pMAL using the Nde1 and Sal1 cloning sites, the pMAL_UGT76G1 plasmid was transformed into the BL21 expression strain (New England Biolabs BL21 competent E. coli) by heat shock treatment. The resulting cells were cultured on LB agar medium in a petri dish in the presence of ampicillin. Appropriate colonies were selected and grown in liquid LBGKP medium containing ampicillin. Glycerol was added and 400 μL aliquots were stored at -20°C and -80°C.
[0264] A stored aliquot was thawed and added to 30 mL of LBGKP medium. This culture was shaken at 30°C for 8 hours and then used to inoculate 400 mL of production medium containing 60 g / L "Overnight Expression Instant TB Medium" (Novagen, catalog number 71491-5), 10 g / L glycerol, and 50 mg / L ampicillin. The culture was stirred at 20°C, and samples were collected to measure OD and pH. After 40 hours, the cells were harvested by centrifugation and frozen. The resulting wet cell weight was 5.86 g.
[0265] 2.74 g of the obtained pellet were lysed by adding 9.6 mL of "Bugbuster Master Mix" (Novagen, catalog number 71456) and 4.1 mL of water. The lysate was recovered by centrifugation and kept frozen.
[0266] Example 10
[0267] Preparation and activity of UGT76G1 produced using the pMAL plasmid and ArcticExpress expression strain
[0268] The pMAL_UGT76G1 plasmid was transformed into an Arctic Express expression strain (Agilent Arctic Express competent cells) by heat shock treatment. The obtained cells were cultured on LB agar medium in a culture dish in the presence of ampicillin and geneticin. Appropriate colonies were selected and grown in liquid LBGKP medium containing ampicillin and geneticin. Glycerol was added and 400 μL aliquots were stored at -20°C and -80°C.
[0269] The stored aliquot was thawed and added to 30 mL of LBGKP culture medium (containing ampicillin and geneticin). The culture was shaken at 30°C for 8 h and subsequently used to inoculate 400 mL of a production medium containing 60 g / L of "Overnight Expression Instant TB Medium" (Novagen, catalog number 71491-5), 10 g / L glycerol, and 50 mg / L ampicillin. The culture was stirred at 12°C and samples were collected to measure OD (600 nm) and pH. After 68 hours, the cells were harvested by centrifugation and frozen. The wet weight of the cells obtained was 8.96 g.
[0270] 2.47 g of the obtained pellet were lysed by adding 8.73 mL of "Bugbuster Master Mix" (Novagen, catalog number 71456) and 3.79 mL of water. The lysate was recovered by centrifugation and kept frozen.
[0271] Example 11
[0272] Preparation and activity of UGT76G1 produced using the pCOLDIII plasmid and ArcticExpress expression strain
[0273] After subcloning the synthesized UGT76G1 gene into the pCOLDIII plasmid using the Nde1 and Xho1 cloning sites, the pCOLDIII_UGT76G1 plasmid was transformed into an Arctic Express expression strain (Agilent Arctic Express competent cells) by heat shock treatment. The obtained cells were cultured on LB agar medium in a culture dish in the presence of ampicillin and geneticin. Appropriate colonies were selected and grown in liquid LBGKP medium containing ampicillin and geneticin. Glycerol was added and 400 μL aliquots were stored at -20°C and -80°C.
[0274] The stored aliquots were thawed and added to 30 mL of LBGKP culture medium (containing ampicillin and geneticin). The culture was vibrated at 30°C for 8 h and then used to inoculate 400 mL of a production medium containing 60 g / L of "overnight expression instant TB culture medium" (Novagen, catalog number (Cat. No.) 71491-5), 10 g / L glycerol, and 50 mg / L kanamycin. The culture was stirred at 12°C and samples were collected to measure OD (600 nm) and pH. After 63 hours, the cells were harvested by centrifugation and frozen. The wet weight of the cells obtained was 6.54 g.
[0275] 2.81 g of the obtained pellet were lysed by adding 9.8 mL of "Bugbuster Master Mix" (Novagen, catalog number 71456) and 4.2 mL of water. The lysate was recovered by centrifugation and kept frozen.
[0276] Example 12
[0277] Preparation and activity of UGT76G1 produced using the pCOLDIII plasmid and the Origami2(DE3) expression strain
[0278] The pCOLDIII_UGT76G1 plasmid was transformed into the Origami2 (DE3) expression strain (Novagen Origami TM 2 (DE3) competent cells). The resulting cells were cultured on LB agar in a Petri dish in the presence of ampicillin. Appropriate colonies were selected and grown in liquid LBGKP medium containing ampicillin. Glycerol was added and 400 μL aliquots were stored at -20°C and -80°C.
[0279] The stored aliquot was thawed and added to 30 mL of LBGKP culture medium (containing ampicillin). The culture was shaken at 30°C for 8 h and subsequently used to inoculate 400 mL of a production medium containing 60 g / L of "Overnight Expression Instant TB Medium" (Novagen, catalog number 71491-5), 10 g / L glycerol, and 50 mg / L kanamycin. The culture was stirred at 12°C and samples were collected to measure OD (600 nm) and pH. After 68 hours, the cells were harvested by centrifugation and frozen. The wet weight of the cells obtained was 2.53 g.
[0280] 1.71 g of the obtained pellet were lysed by adding 6.0 mL of "Bugbuster Master Mix" (Novagen, catalog number 71456) and 1.9 mL of water. The lysate was recovered by centrifugation and kept frozen.
[0281] Example 13
[0282] Activity determination
[0283] Activity testing for the conversion of stevioside to rebaudioside A and rebaudioside D to rebaudioside X was performed at a 5 mL scale using 500 μL of thawed lysate using 0.5 mM substrate, 2.5 mM UDP-glucose, and 3 mM MgCl2 in 50 mM sodium phosphate buffer, pH 7.2. Samples were collected and analyzed by HPLC. The results for different formulations of UGT76G1 are summarized in the table below.
[0284]
[0285] *Notice
[0286] The activity of stevioside and rebaudioside X conversion is expressed as activity per mL of lysate. 1 U will convert 1 μmol of substrate in 1 hour at 30°C and pH 7.2.
[0287] Example 14
[0288] 50 mL scale reaction for the conversion of rebaudioside D to rebaudioside X
[0289] 5 mL of the lysate from Example 12 was used to convert rebaudioside D to rebaudioside X on a 50 mL scale. The reaction medium consisted of 50 mM sodium phosphate buffer, pH 7.2, 3 mM MgCl2, 2.5 mM UDP-glucose, and 0.5 mM rebaudioside D. After shaking the reaction at 30°C for 90 h, 50 mL of ethanol was added, and the resulting mixture was stirred at -20°C for 1 hour. After centrifugation at 5000 g for 10 min, the supernatant was purified by ultrafiltration (Vivaflow MWCO 30000). 78 mL of permeate was obtained; 9 mL of the retentate was diluted with 9 mL of ethanol and subjected to ultrafiltration again (Vivaflow MWCO 30000). An additional 14 mL of filtrate was obtained and combined with the first permeate. The combined permeate was concentrated under reduced pressure at 30°C until 32 mL of a clear solution was obtained.
[0290] The HPLC trace of the product mixture is shown in Figure 5 HPLC was performed on an Agilent 1200 series equipped with a binary pump, autosampler, and thermostat column compartment. The method was isocratic, with a mobile phase consisting of 70% water (0.1% formic acid): 30% acetonitrile. The flow rate was 0.1 μL / min. The column used was a Phenomenex Prodigy 5μ ODS(3)100A; 250 x 2 mm. The column temperature was maintained at 40°C. The injection volume was 20-40 μL.
[0291] Example 15
[0292] Preparation of UGT91D2 using the pMAL plasmid and BL21 expression strain
[0293] After subcloning the synthesized UGT91D2 gene into the pMAL plasmid using the Nde1 and Sal1 cloning sites, the pMAL_UGT91D2 plasmid was transformed into the BL21 expression strain (New England Biolabs BL21 competent E. coli) by heat shock treatment. The obtained cells were cultured on LB agar medium in a culture dish in the presence of ampicillin. Appropriate colonies were selected and grown in liquid LBGKP medium containing ampicillin. Glycerol was added and 400 μL aliquots were stored at -20°C and -80°C.
[0294] A stored aliquot was thawed and added to 30 mL of LBGKP medium. This culture was shaken at 30°C for 8 hours and then used to inoculate 400 mL of production medium containing 60 g / L "Overnight Expression Instant TB Medium" (Novagen, catalog number 71491-5), 10 g / L glycerol, and 50 mg / L ampicillin. The culture was stirred at 20°C, and samples were collected to measure OD and pH. After 40 hours, the cells were harvested by centrifugation and frozen. The resulting wet cell weight was 12.32 g.
[0295] 2.18 g of the obtained pellet were lysed by adding 7.7 mL of "Bugbuster Master Mix" (Novagen, catalog number 71456) and 3.2 mL of water. The lysate was recovered by centrifugation and used directly for activity testing.
[0296] Example 16
[0297] Production of UGT91D2 using the pMAL plasmid and ArcticExpress expression strain
[0298] The pMAL_UGT91D2 plasmid was transformed into an Arctic Express expression strain (Agilent Arctic Express competent cells) by heat shock treatment. The obtained cells were cultured on LB agar medium in a culture dish in the presence of ampicillin and geneticin. Appropriate colonies were selected and grown in liquid LBGKP medium containing ampicillin and geneticin. Glycerol was added and 400 μL aliquots were stored at -20°C and -80°C.
[0299] The stored aliquots were thawed and added to 30 mL of LBGKP culture medium (containing ampicillin and geneticin). The culture was vibrated at 30°C for 8 h and then used to inoculate 400 mL of a production medium containing 60 g / L of "overnight expression instant TB culture medium" (Novagen, catalog number (Cat. No.) 71491-5), 10 g / L glycerol, and 50 mg / L ampicillin. The culture was stirred at 20°C for 16 h, then stirred at 12°C for 50 h, and samples were collected to measure OD (600 nm) and pH. The cells were harvested by centrifugation and frozen. The wet weight of the cells obtained was 15.77 g.
[0300] 2.57 g of the obtained precipitate were lysed by adding 9.0 mL of "Bugbuster Master Mix" (Novagen, catalog number 71456) and 3.8 mL of water. The lysate was recovered by centrifugation and used directly for activity testing.
[0301] Example 17
[0302] Preparation of UGT91D2 using pET30a+ plasmid and Tuner (DE3) expression strain
[0303] The pET30a+_UGT91D2 plasmid was transformed into the Tuner (DE3) expression strain (Novagen Tuner) by heat shock treatment. tm (DE3 competent cells). The obtained cells were cultured on LB agar in a petri dish in the presence of kanamycin. Appropriate colonies were selected and grown in liquid LBGKP medium (containing kanamycin). Glycerol was added and 400 μL aliquots were stored at -20°C and -80°C.
[0304] The stored aliquot was thawed and added to 100 mL of LB medium containing 50 mg / L kanamycin. The culture was shaken at 30°C for 15 h. 6.2 mL of this culture was used to inoculate 500 mL of production medium containing LB. The medium was stirred at 37°C until an OD (600 nm) of 0.9 was obtained, followed by the addition of 500 μL of 100 mM IPTG solution (the IPTG concentration in the medium was 100 μM), and the medium was stirred at 30°C for 4 hours. The cells were harvested by centrifugation and frozen. The wet weight of the cells obtained was 4.02 g.
[0305] 1.92 g of the obtained pellet were lysed by adding 6.8 mL of "Bugbuster Master Mix" (Novagen, catalog number 71456) and 2.8 mL of water. The lysate was recovered by centrifugation and directly tested for its activity.
[0306] Example 18
[0307] Preparation of UGT91D2 using pET30a+ plasmid and ArcticExpress expression strain
[0308] The pET30a+_UGT91D2 plasmid was transformed into ArcticExpress (DE3) expression strain (Agilent ArcticExpress competent cells) by heat shock treatment. The cells obtained were cultured on LB agar medium in a culture dish in the presence of kanamycin and geneticin. Appropriate bacterium colonies were selected and grown in liquid LBGKP medium (containing kanamycin and geneticin). Glycerol was added and 400 μL aliquots were stored at -20°C and -80°C.
[0309] The stored aliquots were thawed and added to 30 mL of LBGKP culture medium (containing kanamycin and geneticin). The culture was vibrated at 30°C for 8 h and then used to inoculate 400 mL of a production medium containing 60 g / L of "overnight expression instant TB culture medium" (Novagen, catalog number (Cat. No.) 71491-5), 10 g / L glycerol, and 50 mg / L ampicillin. The culture was stirred at 20°C for 16 h, then stirred at 12°C for 50 h, and samples were collected to measure OD (600 nm) and pH. After 60 hours, the cells were harvested by centrifugation and frozen. The wet weight of the cells obtained was 16.07 g.
[0310] 3.24 g of the obtained precipitate were lysed by adding 11.4 mL of "Bugbuster Master Mix" (Novagen, catalog number 71456) and 4.8 mL of water. The lysate was recovered by centrifugation and used directly for activity testing.
[0311] Example 19
[0312] Determination of the activity of in vivo preparations of UGT91D2
[0313] Activity testing for the conversion of rubusoside to stevioside was performed on a 5 mL scale using 1000 μL of lysate using 0.5 mM substrate, 2.5 mM UDP-glucose, and 3 mM MgCl2 in 50 mM sodium phosphate buffer, pH 7.2. Samples were collected and analyzed by HPLC. The results for different preparations of UGT91D2 are summarized in the table below.
[0314]
[0315] *Note: Activity is expressed per mL of lysate. 1 U will convert 1 μmol of substrate in 1 hour at 30°C and pH 7.2.
[0316] Example 20
[0317] Isolation of Rebaudioside X
[0318] The amount of the product mixture of Example 14 was not large enough to be separated by preparative HPLC. Therefore, analytical HPLC with a series of injections was used to separate the components of the mixture. Separation was performed as described above in Example 14 to provide the product corresponding to Figure 5 The HPLC trace of the product contained two main peaks: fraction A (retention time 24.165 minutes) and fraction B (retention time 31.325 minutes).
[0319] The retention time of fraction A coincided with reb D, indicating unreacted starting material from the bioconversion reaction.
[0320] The retention time of purified fraction B ( Figure 6 ) is consistent with reb X, indicating successful bioconversion from reb D. The HPLC trace of the purified fraction B was shown in FIG. Figure 7 The identity of the material collected in fraction B as reb X was confirmed by co-injection of fraction B. It was found that fraction B and reb X standards eluted at the same retention time ( Figure 8 ), which indicates that fraction B is reb X.
[0321] The identity of fraction B as reb X was also confirmed by NMR and HRMS. For sampling, fraction B was concentrated in a rotary evaporator, freeze-dried, and dried (at 40° C., 40 h).
[0322] The NMR samples were dissolved in deuterated pyridine (C5D5N) and spectra were acquired on a Varian Unity Plus 600 MHz instrument using a standard pulse sequence. The NMR spectrum of fraction B was compared with that of reb X. The two spectra were superimposed ( Figure 9 ) showed that fraction B was consistent with the peak of reb X. The NMR assignments of reb X are shown in the following table:
[0323] C5D5N a-c Rebaudioside X 1 H and 13 C NMR spectral data
[0324]
[0325]
[0326]
[0327] a The attribution was confirmed based on COSY, HMQC, and HMBC correlations; b Chemical shift values are expressed in δ (ppm); c Coupling constants are expressed in Hz.
[0328] HRMS ( Figure 10The sample was dissolved in methanol, eluted in 2:2:1 methanol:acetonitrile:water, and introduced by infusion using the onboard syringe pump. [M+Na] + adduct (which corresponds to C 56 H 90 O 33 The molecular formula of reb X was confirmed.
[0329]
[0330] This application also includes the following implementation plans:
[0331] Embodiment 1. A method for producing highly purified target steviol glycosides, comprising the steps of:
[0332] a. Providing a starting composition comprising a substrate steviol glycoside;
[0333] b. Provide UDP-glucosyltransferase;
[0334] c. optionally providing a biocatalyst capable of overproduction and recycling of UDP-glucose and a substrate for said recycling;
[0335] d. contacting a UDP-glucosyltransferase with a medium comprising a starting composition to produce a composition comprising a target steviol glycoside comprising one or more additional glucose units compared to the substrate steviol glycoside; and
[0336] e. separating the target steviol glycoside from the medium to provide a highly purified target steviol glycoside composition.
[0337] Embodiment 2. The method of embodiment 1, wherein the substrate steviol glycoside is selected from the group consisting of stevioside, steviol diglycoside, rubusoside, dulcoside B, dulcoside A, rebaudioside B, rebaudioside G, stevioside, rebaudioside C, rebaudioside F, rebaudioside A, rebaudioside I, rebaudioside E, rebaudioside H, rebaudioside L, rebaudioside K, rebaudioside J, rebaudioside X, rebaudioside D, rebaudioside N, rebaudioside O, synthetic steviol glycosides, and combinations thereof.
[0338] Embodiment 3. The method of embodiment 1, wherein the UDP-glucosyltransferase is a UDP-glucosyltransferase capable of catalyzing the glucosylation of rubusoside to stevioside, stevioside to reb A, reb A to reb D, and / or reb D to reb X.
[0339] Embodiment 4. The method of embodiment 1, wherein when the substrate steviol glycoside is rubusoside and the target steviol glycoside is stevioside, the UDP-glucosyltransferase is UGT91D2, when the substrate steviol glycoside is stevioside and the target steviol glycoside is reb A, the UDP-glucosyltransferase is UGT76G1, when the substrate steviol glycoside is reb A and the target steviol glycoside is reb D, the UDP-glucosyltransferase is UGT91D2, or when the substrate steviol glycoside is reb D and the target steviol glycoside is reb X, the UDP-glucosyltransferase is UGT76G1.
[0340] Embodiment 5. The method of embodiment 1, wherein the UDP-glucosyltransferase is expressed in a microorganism selected from Escherichia coli, a species of Saccharomyces, a species of Aspergillus, a species of Pichia, or another suitable microorganism suitable for accommodating a UDP-glucosyltransferase gene and its subsequent expression.
[0341] Embodiment 6. The method of embodiment 1, wherein in step (c), the biocatalyst is expressed in a microorganism selected from Escherichia coli, Saccharomyces spp., Aspergillus spp., Pichia spp., or another microorganism suitable for UDP-glucose recycling enzyme genes and their subsequent expression and function.
[0342] Embodiment 7. The method of embodiment 1, wherein the UDP-glucosyltransferase in step (b) and optionally the biocatalyst in step (c) are contained in the same microbial cell.
[0343] Embodiment 8. The method of embodiment 1, wherein the UDP-glucosyltransferase in step (b) and / or the biocatalyst in step (c) are used in free or immobilized form as crude, semi-purified and purified enzyme preparations, living microbial cells, intact microbial cells, cell lysates and / or any other form of biocatalyst known in the art.
[0344] Embodiment 9. The method of embodiment 1, wherein the target steviol glycoside is selected from stevioside, reb A, reb D, reb X, and mixtures thereof.
[0345] Embodiment 10. The method of embodiment 1, wherein the target steviol glycoside is separated from the reaction medium using crystallization, separation by membranes, centrifugation, extraction, chromatography, or a combination of said methods.
[0346] Embodiment 11. The method of embodiment 1, wherein the substrate steviol glycoside is rubusoside and the target steviol glycoside is stevioside.
[0347] Embodiment 12. The method of embodiment 1, wherein the substrate steviol glycoside is stevioside and the target steviol glycoside is reb A.
[0348] Embodiment 13. The method of embodiment 1, wherein the substrate starting steviol glycoside is reb A and the target steviol glycoside is reb D.
[0349] Embodiment 14. The method of embodiment 1, wherein the substrate steviol glycoside is reb D and the target steviol glycoside is reb X.
[0350] Embodiment 15. The method of Embodiment 1, wherein steps (a)-(e) are repeated.
[0351] Embodiment 16. The method of Embodiment 15, wherein steps (a)-(e) are repeated once.
[0352] Embodiment 17. The method of Embodiment 15, wherein steps (a)-(e) are repeated twice.
[0353] Embodiment 18. The method of embodiment 1, wherein the target steviol glycoside content is greater than about 95% by dry weight.
[0354] Embodiment 19. The method of embodiment 18, wherein the target steviol glycoside is selected from stevioside, reb A, reb D, and reb X.
[0355] Embodiment 20. The method of Embodiment 18, wherein the target steviol glycoside is reb X.
[0356] Embodiment 21. A highly purified target steviol glycoside composition prepared according to the method of embodiment 1, wherein the target steviol glycoside content is greater than about 95% by dry weight.
[0357] Embodiment 22. The highly purified target steviol glycoside composition of embodiment 21, wherein the target steviol glycoside is selected from reb D and reb X.
[0358] Embodiment 23. A highly purified target steviol glycoside composition prepared according to the method of embodiment 1, wherein the target steviol glycoside is polymorphic.
[0359] Embodiment 24. The highly purified target steviol glycoside composition of embodiment 23, wherein the target steviol glycoside is reb D or reb X.
[0360] Embodiment 25. A consumable product comprising the highly purified target glycoside composition of embodiment 1, wherein the product is selected from the group consisting of a food, a beverage, a pharmaceutical composition, a smoking product, a nutraceutical composition, an oral hygiene composition, and a cosmetic composition.
[0361] Embodiment 26. A consumable product comprising the highly purified target steviol glycoside composition of embodiment 1, wherein the product is selected from the group consisting of a food, a beverage, a pharmaceutical composition, a smoking product, a nutraceutical composition, an oral hygiene composition, and a cosmetic composition, and wherein the target steviol glycoside is reb D.
[0362] Embodiment 26. A consumable product comprising the highly purified target steviol glycoside composition of embodiment 1, wherein the product is selected from the group consisting of a food, a beverage, a pharmaceutical composition, a smoking product, a nutraceutical composition, an oral hygiene composition, and a cosmetic composition, and wherein the target steviol glycoside is reb X. Sequence Listing <110> PureCircle Limited Liability Company <120> High-purity steviol glycosides <130> 39227-22WO <160> 2 <170> PatentIn version 3.5 <210> 1 <211> 1397 <212> DNA <213> Escherichia coli <400> 1 ccatggccca tatggaaaac aaaaccgaaa ccaccgttcg tcgtcgtcgc cgtattattc 60 tgtttccggt tccgtttcag ggtcatatta atccgattct gcagctggca aatgtgctgt 120 atagcaaagg ttttagcatt accatttttc ataccaattt taacaaaccg aaaaccagca 180 attatccgca ttttaccttt cgctttatattc tggataatga tccgcaggat gaacgcatta 240 gcaatctgcc gacacatggt ccgctggcag gtatgcgtat tccgattatt aacgaacatg 300 gtgcagatga actgcgtcgt gaactggaac tgctgatgct ggcaagcgaa gaagatgaag 360 aagttagctg tctgattacc gatgcactgt ggtattttgc acagagcgtt gcagatagcc 420 tgaatctgcg tcgtctggtt ctgatgacca gcagcctgtt taactttcat gcacatgtta 480 gcctgccgca gtttgatgaa ctgggttatc tggatccgga tgataaaacc cgtctggaag 540 aacaggcaag cggttttccg atgctgaaag tgaaagatat caaaagcgcc tatagcaatt 600 ggcagattct gaaagaaatt ctgggcaaaa tgattaaaca gaccaaagca agcagcggtg 660 ttatttggaa tagctttaaa gaactggaag aaagcgaact ggaaaccgtg attcgtgaaa 720 ttccggcacc gagctttctg attccgctgc cgaaacatct gaccgcaagc agcagcagcc 780 tgctggatca tgatcgtacc gtttttcagt ggctggatca gcagcctccg agcagcgttc 840 tgtatgttag ctttggtagc accagcgaag ttgatgaaaa agattttctg gaaattgccc 900 gtggtctggt tgatagcaaa cagagctttc tgtgggttgt tcgtccgggt tttgttaaag 960 gtagcacctg ggttgaaccg ctgccggatg gttttctggg tgaacgtggt cgtattgtta 1020 aatgggttcc gcagcaagaa gttctggcac acggcgcaat tggtgcattt tggacccata 1080 gcggttggaa tagcaccctg gaaagcgttt gtgaaggtgt tccgatgatt tttagcgatt 1140 ttggtctgga tcagccgctg aatgcacgtt atatgagtga tgttctgaaa gtgggtgtgt 1200 atctggaaaa tggttgggaa cgtggtgaaa ttgcaaatgc aattcgtcgt gttatggtgg 1260 atgaagaagg tgaatatatt cgtcagaatg cccgtgttct gaaacagaaa gcagatgtta 1320 gcctgatgaa aggtggtagc agctatgaaa gcctggaaag tctggttagc tatattagca 1380 gcctgtaata actcgag 1397 <210> 2 <211> 1442 <212> DNA <213> Escherichia coli <400> 2 ccatggcaca tatggcaacc agcgatagca ttgttgatga tcgtaaacag ctgcatgttg 60 caacctttcc gtggctggca tttggtcata ttctgccgta tctgcagctg agcaaactga 120 ttgcagaaaa aggtcataaa gtgagctttc tgagcaccac ccgtaatatt cagcgtctga 180 gcagccatat tagtccgctg attaatgttg ttcagctgac cctgcctcgt gttcaagaac 240 tgccggaaga tgccgaagca accaccgatg ttcatccgga agatattccg tatctgaaaa 300 aagcaagtga tggtctgcag ccggaagtta cccgttttct ggaacagcat agtccggatt 360 ggatcatcta tgattatacc cattattggc tgccgagcat tgcagcaagc ctgggtatta 420 gccgtgcaca ttttagcgtt accaccccgt gggcaattgc atatatgggt ccgagcgcag 480 atgcaatgat taatggtagt gatggtcgta ccaccgttga agatctgacc acccctccga 540 aatggtttcc gtttccgacc aaagtttgtt ggcgtaaaca tgatctggca cgtctggttc 600 cgtataaagc accgggtatt agtgatggtt atcgtatggg tctggttctg aaaggtagcg 660 attgtctgct gagcaaatgc tatcatgaat ttggcaccca gtggctgccg ctgctggaaa 720 ccctgcatca ggttccggtt gttccggtgg gtctgctgcc tccggaagtt ccgggtgatg 780 aaaaagatga aacctgggtt agcatcaaaa aatggctgga tggtaaacag aaaggtagcg 840 tggtttatgt tgcactgggt agcgaagttc tggttagcca gaccgaagtt gttgaactgg 900 cactgggtct ggaactgagc ggtctgccgt ttgtttgggc atatcgtaaa ccgaaaggtc 960 cggcaaaaag cgatagcgtt gaactgccgg atggttttgt tgaacgtacc cgtgatcgtg 1020 gtctggttg gaccagctgg gcacctcagc tgcgtattct gagccatgaa agcgtttgtg 1080 gttttctgac ccattgtggt agcggtagca ttgtggaagg tctgatgttt ggtcatccgc 1140 tgattgct gccgattttt ggtgatcagc cgctgaatgc acgtctgctg gaagataaac 1200 aggttggtat tgaaattccg cgtaatgaag aagatggttg cctgaccaaa gaaagcgttg 1260 cacgtagcct gcgtagcgtt gttgttgaaa aagaaggcga aatctataaa gccaatgcac 1320 gtgaactgag caaaatctat aatgatacca aagtggaaaa agaatatgtg agccagttcg 1380 tggattatct ggaaaaaac acccgtgcag ttgccattga tcacgaaagc taatgactcg 1440 of 1442
Claims
1. A method of adding at least one glucose unit to rebaudioside D, rebaudioside A or stevioside contained in a starting composition to provide rebaudioside X, wherein the method comprises (I) In the case where the starting composition contains rebaudioside D (a) contacting rebaudioside D in the starting composition with UDP-glucosyltransferase UGT76G1, thereby converting rebaudioside D into rebaudioside X; (II) In the case where rebaudioside A is included in the starting composition (a) contacting rebaudioside A in the starting composition with UDP-glucosyltransferase UGT91D2, thereby converting rebaudioside A into rebaudioside D, and (b) contacting the composition comprised in step (a) with UDP-glucosyltransferase UGT76G1, thereby converting rebaudioside D to rebaudioside X; or (III) In the case where the starting composition contains stevioside (a) contacting the stevioside in the starting composition with UDP-glucosyltransferase UGT76G1, thereby converting the stevioside into rebaudioside A, (b) contacting the composition contained in step (a) with UDP-glucosyltransferase UGT91D2, thereby converting rebaudioside A to rebaudioside D, and (c) contacting the composition contained in step (b) with UDP-glucosyltransferase UGT76G1, thereby converting rebaudioside D to rebaudioside X, and The structure of Rebaudioside X is:
2. The method of claim 1, wherein the starting composition comprises purified or partially purified rebaudioside D, rebaudioside A or stevioside.
3. The method of claim 1, wherein the starting composition comprises greater than 50% rebaudioside D, rebaudioside A or stevioside.
4. The method of claim 1, wherein the starting composition comprises greater than 90% rebaudioside D, rebaudioside A or stevioside.
5. The method of any of the preceding claims, wherein the Rebaudioside X has a purity greater than 80% by dry weight.
6. The method of any of the preceding claims, wherein the Rebaudioside X has a purity greater than 90% by dry weight.
7. The method of any of the preceding claims, wherein the Rebaudioside X has a purity greater than 95% by dry weight.
8. The method of any one of the preceding claims, wherein the UDP-glucosyltransferase is expressed in a host microorganism.
9. The method of claim 8, wherein the host microorganism is selected from the group consisting of E. coli, Saccharomyces species, Aspergillus species, and Pichia species.
